<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">World J Surg Oncol</journal-id>
      <journal-title-group>
        <journal-title>World Journal of Surgical Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1477-7819</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21752265</article-id>
      <article-id pub-id-type="pmc">3152528</article-id>
      <article-id pub-id-type="publisher-id">1477-7819-9-73</article-id>
      <article-id pub-id-type="doi">10.1186/1477-7819-9-73</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Metastatic collecting duct carcinoma of the kidney treated with sunitinib</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Tazi</surname>
            <given-names>El Mehdi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>moulay.elmehdi@yahoo.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Essadi</surname>
            <given-names>Ismail</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ismail@yahoo.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Tazi</surname>
            <given-names>Mohamed Fadl</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>fadl@yahoo.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Ahellal</surname>
            <given-names>Youness</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>youness@yahoo.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>M'rabti</surname>
            <given-names>Hind</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>hind@yahoo.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Errihani</surname>
            <given-names>Hassan</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>hassan@yahoo.fr</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco</aff>
      <aff id="I2"><label>2</label>Department of Urology, CHU Hassan II, Fez, Morocco</aff>
      <pub-date pub-type="collection">
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <volume>9</volume>
      <fpage>73</fpage>
      <lpage>73</lpage>
      <history>
        <date date-type="received">
          <day>4</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>7</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2011 Tazi et al; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Tazi et al; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.wjso.com/content/9/1/73"/>
      <abstract>
        <p>Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.</p>
      </abstract>
      <kwd-group>
        <kwd>Collecting duct carcinoma</kwd>
        <kwd>Sunitinib</kwd>
        <kwd>Metastasis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Collecting duct carcinoma (CDC) of the kidney, also known as Bellini duct carcinoma, is a rare variant of renal cell carcinoma (RCC) arising from the epithelium of the distal collecting ducts; it accounts for 2% of all RCCs [<xref ref-type="bibr" rid="B1">1</xref>]. Clinically, CDC is characterized by an extremely aggressive phenotype, accompanying metastatic diseases at presentation in most reported cases; the prognosis ofCDC is therefore poor, with approximately 70% of patients dying of disease progression within 2 years after diagnosis. In fact, several systemic therapies, including cytokine therapy and cytotoxic chemotherapy, have failed to achieve favorable response to metastatic CDC except for very limited cases [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Sunitinib is an orally available inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and others, with direct antitumor and antiangiogenic activity. Based on impressive outcomes in several clinical trials, sunitinib has been approved worldwide for treatment of RCC patients with clear cell histology [<xref ref-type="bibr" rid="B8">8</xref>]. Furthermore, significant therapeutic activities of sunitinib against non-clear cell RCCs, for example papillary and chromophobe carcinomas, have also been reported in recent studies [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]; however, it remains unknown whether sunitinib has a therapeutic impact on CDC of the kidney. Here, we report the first case of a patient with metastatic CDC of the kidney who had a favorable response to sunitinib treatment.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>A 47-year-old man with a 14.1 cm left renal mass extending into the renal vein and metastases involving the bilateral lungs and retroperitoneal lymph nodes were referred to our institution.</p>
      <p>Radical left nephrectomy combined with lymphadenectomy was performed. Pathological examination resulted in diagnosis of this case as CDC with tubulopapillary architecture consisting of tumor cells with eosinophilic cytoplasm and high-grade nuclei (Figure <xref ref-type="fig" rid="F1">1</xref>). In addition, immunohistochemical staining was characteristic of CDC; that is, tumor cells were positive for Ulex Europaeus agglutinin (Figure <xref ref-type="fig" rid="F2">2</xref>), cytokeratin 19, 34bE12, epithelial membrane antigen and focally positive with vimentin [<xref ref-type="bibr" rid="B1">1</xref>]. Following radical nephrectomy, this case was treated with sunitinib rather than systemic chemotherapy, considering her poor performance status. After 4 courses of sunitinib therapy with 37,5 mg daily schedule, metastases to the lungs and left rib decreased by more than 30% compared with findings before sunitinib treatment (Figure <xref ref-type="fig" rid="F3">3</xref>). Despite the favorable effects of sunitinib on metastatic diseases, pleural effusion appeared to be remarkable after the administration of sunitinib; however, cytological examination showed no malignant cells in the pleural fluid. In addition to pleural effusion, several adverse events associated with sunitinib treatment, including appetite loss, thrombocytopenias, and hypothyroidism, were observed. Thereafter, disease progression occurred 10 months after the initiation of sunitinib, and the patient died.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Hematoxylin and eosin staining of tissue sections from the nephrectomy specimens demonstrating collecting duct carcinoma (&#xD7; 400)</bold>.</p>
        </caption>
        <graphic xlink:href="1477-7819-9-73-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Tumor showed positive staining for Ulex Europaeus agglutinin</bold>.</p>
        </caption>
        <graphic xlink:href="1477-7819-9-73-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Metastatic lesion to the right lung and left sixth rib before (A) and after (B) 4 courses of sunitinib treatment</bold>.</p>
        </caption>
        <graphic xlink:href="1477-7819-9-73-3"/>
      </fig>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>Because CDC is an uncommon and aggressive disease with extremely poor prognosis, accumulated information about CDC is very limited. Therefore, no established therapy for CDC exists except for surgical resection of localized diseases. To date, however, there have been 14 reported cases of metastatic CDC showing response to systemic therapy, consisting 9, 2, 1, and 1 who were treated by gemcitabine plus cisplatin or carboplatin, paclitaxel plus carboplatin, gemcitabine plus doxorubicin, and interferon-a, respectively [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Considering these findings in addition to the characteristics of CDC similar to those of urothelial cancer, chemotherapy is the currently favored approach for patients with metastatic CDC.</p>
      <p>In the case presented, because of her poor performance status associated with skeletal metastases, it was judged to be difficult to perform intensive systemic chemotherapy. Accordingly, she was treated with sunitinib, which has been regarded as one of the most powerful agents against metastatic RCC [<xref ref-type="bibr" rid="B8">8</xref>], and showed a partial response to this drug. Recently, the favorable clinical activity of sunitinib against non-clear cell carcinomas, including papillary and chromophobe carcinomas, has also been reported [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]; however, this is the first reported case demonstrating a therapeutic response of metastatic CDC to sunitinib. Furthermore, a recent report presented a case of metastatic CDC showing response to sorafenib [<xref ref-type="bibr" rid="B10">10</xref>].</p>
    </sec>
    <sec>
      <title>Conclusion</title>
      <p>Although the precise molecular mechanism involved in the antitumor activity of multiple tyrosine kinase inhibitors against CDC remains largely unknown, these findings suggest that the efficacy of these agents, for example sunitinib and sorafenib, against metastatic CDC needs to be prospectively evaluated.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors' contributions</title>
      <p>EMT, IE, MFT and YA analyzed, interpreted the patient data regarding its oncological features, and has been involved in drafting the manuscript; HM and HE has given final approval of the version to be published. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Srigley</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Eble</surname>
            <given-names>JN</given-names>
          </name>
          <article-title>Collecting duct carcinoma of kidney</article-title>
          <source>Semin Diagn Pathol</source>
          <year>1998</year>
          <volume>15</volume>
          <fpage>54</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="pmid">9503506</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gollob</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Upton</surname>
            <given-names>MP</given-names>
          </name>
          <name>
            <surname>DeWolf</surname>
            <given-names>WC</given-names>
          </name>
          <name>
            <surname>Atkins</surname>
            <given-names>MB</given-names>
          </name>
          <article-title>Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery</article-title>
          <source>Urology</source>
          <year>2001</year>
          <volume>58</volume>
          <fpage>1058</fpage>
          <pub-id pub-id-type="pmid">11744492</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Milowsky</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Rosmarin</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tickoo</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Papanicolaou</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Nanus</surname>
            <given-names>DM</given-names>
          </name>
          <article-title>Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature</article-title>
          <source>Cancer</source>
          <year>2002</year>
          <volume>94</volume>
          <fpage>111</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.10204</pub-id>
          <pub-id pub-id-type="pmid">11815966</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Peyromaure</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thiounn</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Scott&#xE9;</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Vieillefond</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Debr&#xE9;</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases</article-title>
          <source>J Urol</source>
          <year>2003</year>
          <volume>170</volume>
          <fpage>1138</fpage>
          <lpage>1140</lpage>
          <pub-id pub-id-type="doi">10.1097/01.ju.0000086616.40603.ad</pub-id>
          <pub-id pub-id-type="pmid">14501710</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tokuda</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Naito</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Matsuzaki</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Nagashima</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ozono</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Igarashi</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan</article-title>
          <source>J Urol</source>
          <year>2006</year>
          <volume>176</volume>
          <fpage>40</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-5347(06)00502-7</pub-id>
          <pub-id pub-id-type="pmid">16753362</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Banu</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Vieillefond</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Fournier</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Medioni</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Banu</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Duclos</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Rolland</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Escudier</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Arekelyan</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Culine</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-G&#xE9;nitales) study</article-title>
          <source>J Urol</source>
          <year>2007</year>
          <volume>177</volume>
          <fpage>1698</fpage>
          <lpage>1702</lpage>
          <pub-id pub-id-type="doi">10.1016/j.juro.2007.01.063</pub-id>
          <pub-id pub-id-type="pmid">17437788</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chao</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zisman</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pantuck</surname>
            <given-names>AJ</given-names>
          </name>
          <article-title>Collecting duct renal cell carcinoma: clinical study of a rare tumor</article-title>
          <source>J Urol</source>
          <year>2002</year>
          <volume>167</volume>
          <fpage>71</fpage>
          <lpage>74</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-5347(05)65385-2</pub-id>
          <pub-id pub-id-type="pmid">11743278</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rini</surname>
            <given-names>BI</given-names>
          </name>
          <name>
            <surname>Flaherty</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma</article-title>
          <source>Urol Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>543</fpage>
          <lpage>549</lpage>
          <pub-id pub-id-type="doi">10.1016/j.urolonc.2008.03.012</pub-id>
          <pub-id pub-id-type="pmid">18774471</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Choueiri</surname>
            <given-names>TK</given-names>
          </name>
          <name>
            <surname>Plantade</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Elson</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Negrier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ravaud</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rini</surname>
            <given-names>BI</given-names>
          </name>
          <name>
            <surname>Bukowski</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Escudier</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma</article-title>
          <source>J Clin Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <fpage>127</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2007.13.3223</pub-id>
          <pub-id pub-id-type="pmid">18165647</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ansari</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Fatima</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chaudhri</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bhatt</surname>
            <given-names>RI</given-names>
          </name>
          <name>
            <surname>Wallace</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>ND</given-names>
          </name>
          <article-title>Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney</article-title>
          <source>Onkologie</source>
          <year>2009</year>
          <volume>32</volume>
          <fpage>44</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1159/000183736</pub-id>
          <pub-id pub-id-type="pmid">19209019</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
